# ![@NewAmsPharma Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1424851352463753221.png) @NewAmsPharma NewAmsterdam Pharma Corporation

NewAmsterdam Pharma Corporation posts on X about heart, health, in the, chat the most. They currently have [-----] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1424851352463753221/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424851352463753221/c:line/m:interactions.svg)

- [--] Week [------] +625%
- [--] Months [------] +190%
- [--] Year [------] -86%

### Mentions: [--] [#](/creator/twitter::1424851352463753221/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424851352463753221/c:line/m:posts_active.svg)


### Followers: [-----] [#](/creator/twitter::1424851352463753221/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424851352463753221/c:line/m:followers.svg)

- [--] Week [-----] +1.40%
- [--] Months [-----] +18%
- [--] Year [-----] +46%

### CreatorRank: [---------] [#](/creator/twitter::1424851352463753221/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424851352463753221/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  9.72% [travel destinations](/list/travel-destinations)  2.78% [countries](/list/countries)  1.39%

**Social topic influence**
[heart](/topic/heart) 8.33%, [health](/topic/health) 5.56%, [in the](/topic/in-the) 5.56%, [chat](/topic/chat) 5.56%, [ceo](/topic/ceo) 4.17%, [deep](/topic/deep) 4.17%, [events](/topic/events) 4.17%, [study](/topic/study) 4.17%, [future](/topic/future) 2.78%, [science](/topic/science) 2.78%

**Top accounts mentioned or mentioned by**
[@allisonwpeng](/creator/undefined) [@aarti693](/creator/undefined) [@ciccaronecenter](/creator/undefined) [@dukemedicine](/creator/undefined) [@johnkastelein](/creator/undefined) [@alanbrownmd](/creator/undefined) [@mdavidsonmd](/creator/undefined) [@profkausikray](/creator/undefined) [@ahjopen](/creator/undefined) [@ahasciences](/creator/undefined) [@clarivates](/creator/undefined) [@thefhfoundation](/creator/undefined) [@jefferies](/creator/undefined) [@jpreventionalz1](/creator/undefined) [@johnkasteleins](/creator/undefined) [@stifel](/creator/undefined) [@americanhearthttpstco4iycn7sxpz](/creator/undefined) [@jahaaha](/creator/undefined) [@drlipid](/creator/undefined) [@andrearilli](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last [--] hours

"This week results from our Phase [--] clinical program were shared in late-breaking sessions at #EASCongress2025 and simultaneously published in two prestigious medical journals. Learn more about the data: https://bit.ly/4daBzdu https://bit.ly/4daBzdu"  
[X Link](https://x.com/NewAmsPharma/status/1920811850368745838)  2025-05-09T12:03Z [----] followers, 10.9K engagements


"Lowering LDL-C is essential for cardiovascular risk reduction but its not enough on its own. Our CEO Dr. Michael Davidson details why the future of hyperlipidemia management needs to go beyond LDL-C. https://bit.ly/3LAQSCA https://bit.ly/3LAQSCA"  
[X Link](https://x.com/NewAmsPharma/status/1988985206267662519)  2025-11-13T15:00Z [----] followers, 15.5K engagements


"A recent study found only 40% of ASCVD patients achieved guideline-recommended LDL-C targets highlighting the need for frequent follow-up patient counseling and combination therapies. Learn more about the unmet need in cardiovascular disease: https://www.newamsterdampharma.com/unmet-need-cardiovascular-disease/utm_source=x&utm_medium=organic&utm_campaign=ascvd https://www.newamsterdampharma.com/unmet-need-cardiovascular-disease/utm_source=x&utm_medium=organic&utm_campaign=ascvd"  
[X Link](https://x.com/NewAmsPharma/status/1990800560241717615)  2025-11-18T15:13Z [----] followers, [---] engagements


"Our deep commitment to scientific excellence is matched by a culture rooted in patient care. That ethos is embodied in our leadershipincluding our CEO Dr. Michael Davidson who still sees patients on a monthly basis. If youd like to work with a company driven by patient outcomes review our open roles: https://www.newamsterdampharma.com/careers/utm_source=x&utm_medium=organic&utm_campaign=careers https://twitter.com/i/web/status/1991547519822885182 https://www.newamsterdampharma.com/careers/utm_source=x&utm_medium=organic&utm_campaign=careers https://twitter.com/i/web/status/1991547519822885182"  
[X Link](https://x.com/NewAmsPharma/status/1991547519822885182)  2025-11-20T16:41Z [----] followers, [---] engagements


"Lp(a) isnt as well-known as LDL-C but high levels can sharply increase the risk of heart attacks and strokeseven in people with normal LDL. This recent Washington Post article explores the science behind Lp(a) its genetic roots and why its gaining attention among researchers and clinicians. https://wapo.st/48vKTaV https://wapo.st/48vKTaV"  
[X Link](https://x.com/NewAmsPharma/status/1992981809681052012)  2025-11-24T15:41Z [----] followers, [----] engagements


"Join us forinsideperspectives from our leadership team at these December conferences. Can't attend live You'll find on-demand replays on our website. https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-participate-upcoming-investor-conferences-4utm_source=x&utm_medium=organic&utm_campaign=conferences&utm_content=december https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-participate-upcoming-investor-conferences-4utm_source=x&utm_medium=organic&utm_campaign=conferences&utm_content=december"  
[X Link](https://x.com/NewAmsPharma/status/1995493092947030472)  2025-12-01T14:00Z [----] followers, [---] engagements


"Cholesterol isnt just important for heart healthits also vital for the brain. ApoE-bound lipoproteins move cholesterol to the cells that depend on itmaking it central to understanding the connection between cholesterol and Alzheimers disease. https://www.newamsterdampharma.com/lipid-related-conditions/utm_source=x&utm_medium=organic&utm_campaign=ad https://www.newamsterdampharma.com/lipid-related-conditions/utm_source=x&utm_medium=organic&utm_campaign=ad"  
[X Link](https://x.com/NewAmsPharma/status/1998775240869200366)  2025-12-10T15:22Z [----] followers, [----] engagements


"Happy holidays and best wishes for a healthy and joyful New Year from all of us at NewAmsterdam Pharma As we look ahead to [----] we remain committed to advancing our lead investigational asset and exploring new ways to address the global impact of cardiovascular disease"  
[X Link](https://x.com/NewAmsPharma/status/2001314093660057805)  2025-12-17T15:30Z [----] followers, [---] engagements


"As [----] winds down were proud to look back on a year of meaningful momentum. One standout milestone: seeing data from our Phase [--] CETP inhibitor program featured at multiple major conferences and published in several top-tier journals. Huge thanks to our team collaborators and community. Heres to continued progress in 2026"  
[X Link](https://x.com/NewAmsPharma/status/2003123196502094327)  2025-12-22T15:19Z [----] followers, [---] engagements


"Happy New Year from all of us at NewAmsterdam Pharma Were excited for what [----] has in store particularly as we continue to advance PREVAIL our Phase [--] cardiovascular outcomes trial. The stage is set for another year of progress"  
[X Link](https://x.com/anyuser/status/2006742206946607550)  2026-01-01T15:00Z [----] followers, [---] engagements


"We showcased our Phase [--] CETP inhibitor clinical data at multiple major conferences and published findings in top-tier journals throughout [----]. With strong momentum behind our science [----] is shaping up to be another landmark year. Explore our strategic priorities for the year ahead: https://bit.ly/4sv2qYU https://bit.ly/4sv2qYU"  
[X Link](https://x.com/NewAmsPharma/status/2009613473114628166)  2026-01-09T13:09Z [----] followers, [----] engagements


"The earlier we start managing cholesterol the more we can do to prevent heart disease stroke and other complications later in life. Drs. @alanbrownmd and @mdavidsonmd explain why addressing LDL-C from an early age can have a profound impact on a persons long-term cardiovascular health. Learn more about LDL-C goals guidelines and treatment strategies: https://www.expectmoreforldl.com/ldl-c-goals-guidelines-and-treatment https://www.expectmoreforldl.com/ldl-c-goals-guidelines-and-treatment"  
[X Link](https://x.com/NewAmsPharma/status/2013995612359078159)  2026-01-21T15:22Z [----] followers, [----] engagements


"Research suggests that sustaining lower LDL-C over time may delay ASCVD events by decades. The impact of long-term prevention can be profound and the opportunity to improve outcomes is clear. https://www.expectmoreforldl.com/ldl-c-goals-guidelines-and-treatment https://www.expectmoreforldl.com/ldl-c-goals-guidelines-and-treatment"  
[X Link](https://x.com/NewAmsPharma/status/2016182208923672877)  2026-01-27T16:11Z [----] followers, [----] engagements


"On Wear Red Day were shining a light on a risk that often hides in plain sight: as estrogen declines during menopause cardiovascular risk rises. Early awareness and proactive care can make a meaningful difference. Through lifestyle changes routine risk assessment and when appropriate medical therapy women can take control of their long-term heart health. Learn more about risk factors associated with cardiovascular disease. https://www.newamsterdampharma.com/our-focus/ https://www.newamsterdampharma.com/our-focus/"  
[X Link](https://x.com/NewAmsPharma/status/2019800186764345471)  2026-02-06T15:47Z [----] followers, [---] engagements


"Congratulations to Drs. @AllisonWPeng and @aarti693 on receivingNewAmsterdam Pharma'sYoung Researcher Award (YRA)a program supporting early-career investigators advancing innovative research in lipid biology cardiovascular disease and related metabolic conditions. Dr. Peng isa cardiovascular diseasefellow at the Johns Hopkins @CiccaroneCenter whose research focuses on cardiovascular prevention and imaging applying AI and large datasets to improve risk assessment and early detection of ASCVD. She earned her engineering degree from Columbia University and completedherinternal medicine residency"  
[X Link](https://x.com/NewAmsPharma/status/2020914934339813480)  2026-02-09T17:37Z [----] followers, [----] engagements


"Ian Somaiya Chief Financial Officer and Matthew Philippe Executive Vice President Head of Investor Relations willparticipatein a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summittomorrow. A live webcast will be available through the investor relations section ofourwebsite: https://lnkd.in/g2ptjAQd https://lnkd.in/g2ptjAQd"  
[X Link](https://x.com/NewAmsPharma/status/2021312385294925905)  2026-02-10T19:56Z [----] followers, [---] engagements


"Nearly [--] years ago statins reshaped lipid management. Since then additional therapies have expanded treatment options but many patients still do not reach recommended LDL-C goals. As we enter the next era of lipid-lowering therapy there is a meaningful opportunity to provide solutions that are effective well-tolerated and easier for patients and providers to manage helping more people achieve LDL-C levels associated with better cardiovascular health. Learn more about evolving treatment considerations and what patients and clinicians can expect next: https://www.expectmoreforldl.com/"  
[X Link](https://x.com/NewAmsPharma/status/2021970555101229136)  2026-02-12T15:32Z [----] followers, 11.3K engagements


"Atherosclerosis develops quietly long before symptoms appear. For many its not just lifestyleits genetics inherited risk and the way their blood vessels respond to the world around them. Listen as @ProfKausikRay explains why caring for your blood vessels today can prevent urgent problems tomorrow. Learn more about cardiovascular risk factors: https://bit.ly/3NUeOSE https://bit.ly/3NUeOSE"  
[X Link](https://x.com/NewAmsPharma/status/2018720686081192407)  2026-02-03T16:18Z [----] followers, [---] engagements


"Alzheimers and Dementia Care Education Week is a timely reminder that understanding and managing lipids may support long-term brain health and overall well-being. Learn more about the connection between lipids and Alzheimers disease: https://bit.ly/4qFdvVi https://bit.ly/4qFdvVi"  
[X Link](https://x.com/NewAmsPharma/status/2023437567128203667)  2026-02-16T16:41Z [----] followers, [---] engagements


"Meet Lina Gugucheva our Chief Business Officer Lina has more than a decade of experience executing strategic life sciences business development transactions. Meet the leadership team at the helm of our efforts to create transformational therapies: https://bit.ly/3EXev0H https://bit.ly/3EXev0H"  
[X Link](https://x.com/NewAmsPharma/status/1544770423086252039)  2022-07-06T19:49Z [---] followers, [--] engagements


"The Global Burden of Disease Study found that high LDL-c is the second most impactful metabolic risk factor as measured by DALYs raising the risk of both heart disease and stroke. We've made it our goal to deliver a simple oral and potent LDL-lowering treatment to help mitigate these risks"  
[X Link](https://x.com/NewAmsPharma/status/1690041456411521034)  2023-08-11T16:44Z [---] followers, [----] engagements


"Were excited to welcome BJ Jones as our Chief Commercial Officer. BJ brings more than [--] years of commercial and launch experience including mass market launch strategies for industry-leading brands. This appointment comes at an important time as we prepare to evolve into a commercial organization. I am excited to be a part of NewAmsterdam Pharma BJ says. I look forward to leveraging my experience to build NewAmsterdams commercial team and to partnering with management to unlock obicetrapibs value for patients worldwide"  
[X Link](https://x.com/NewAmsPharma/status/1691182234286301184)  2023-08-14T20:17Z [---] followers, [----] engagements


"Meet Matthew Philippe our Executive Vice President and Head of Investor Relations. Matt joined our management team earlier this year adding his insights from nearly [--] years of healthcare investing and corporate finance experience"  
[X Link](https://x.com/NewAmsPharma/status/1703786439790534761)  2023-09-18T15:01Z [---] followers, [--] engagements


"Research published in @AHJ_Open found that just 3.2% of all U.S. adults with ASCVD were receiving an add-on lipid lowering therapy (LLT) compared to 61.4% of the same population recommended to add an LLT according to the AHA/ACC cholesterol guideline. We're investigating #CETP inhibition as a potential add-on LLT and observed a median 63.4% reduction in LDL-C for patients in our Phase [--] ROSE2 study who received a combination of our CETP inhibitor and ezetimibe"  
[X Link](https://x.com/NewAmsPharma/status/1717184500436779433)  2023-10-25T14:21Z [---] followers, [---] engagements


"Were excited to present data from our Phase 2b Japan Trial in an oral plenary session at @AHAScience's Scientific Sessions. The results of this trial are consistent with our other studies which reinforces our belief that our #CETP inhibitor obicetrapib could be a paradigm-changing medicine across all populations. #AHA23"  
[X Link](https://x.com/NewAmsPharma/status/1723340597040234905)  2023-11-11T14:03Z [---] followers, [---] engagements


"Were proud to congratulate our Chief Scientific Officer Dr. @JohnKastelein on two recent honors. First he was named to @Clarivates [----] list of Highly Cited Researchers selected for authoring influential valuable publications in clinical medicine. In addition a paper he co-authored on #CETP inhibition and its potential preventive effect on major adverse cardiovascular events was also noted as one of the top-viewed papers in the International Journal of Molecular Sciences"  
[X Link](https://x.com/NewAmsPharma/status/1730581092736827422)  2023-12-01T13:34Z [---] followers, [----] engagements


"Lp(a) is thought to be more atherogenic than other ApoB-containing lipoproteins despite carrying less cholesterol. In two consecutive clinical studies ROSE and ROSE2 we observed that participants taking our #CETP inhibitor obicetrapib on top of high-intensity statins saw significant reductions in Lp(a) levels in addition to significant reductions in LDL-C"  
[X Link](https://x.com/NewAmsPharma/status/1732776332658925752)  2023-12-07T14:57Z [---] followers, 18.3K engagements


"About 2/3 of U.S. adults say they've had their #cholesterol checked in the past [--] years which is essential because high cholesterol has no symptoms and raises the risk for heart disease and stroke. This American Heart Month learn more about your risk for high cholesterol--and the steps you can take to reduce that risk"  
[X Link](https://x.com/NewAmsPharma/status/1753081585816023046)  2024-02-01T15:43Z [---] followers, [---] engagements


"We observed a median 63.4% reduction in LDL-C among patients taking our potent CETP inhibitor obicetrapib and ezetimibe on top of high-intensity statins in our ROSE2 trial. Our pivotal Phase [--] trial TANDEM will evaluate a fixed-dose combination of the two therapies"  
[X Link](https://x.com/NewAmsPharma/status/1775986695759949881)  2024-04-04T20:39Z [---] followers, 264.8K engagements


"This #MemorialDay we honor and remember the brave men and women who made the ultimate sacrifice for our country. Their courage and dedication inspire us every day. #NeverForget"  
[X Link](https://x.com/NewAmsPharma/status/1795157507825950944)  2024-05-27T18:17Z [---] followers, [---] engagements


"Research from @TheFHFoundation shows only 2.2% of high-risk Americans ever receive more than one lipid-lowering medication. Combination therapy could potentially help more people reach their LDL-C goals reducing the risk of cardiovascular disease. https://bit.ly/3xjhb9A https://bit.ly/3xjhb9A"  
[X Link](https://x.com/NewAmsPharma/status/1802698528558370830)  2024-06-17T13:43Z [---] followers, [----] engagements


"Listen in to a fireside chat with our Chief Financial Officer Ian Somaiya live from the Morgan Stanley Global Healthcare Conference at [--] a.m. ET. https://bit.ly/3Xw1wOp https://bit.ly/3Xw1wOp"  
[X Link](https://x.com/NewAmsPharma/status/1832034204147646966)  2024-09-06T12:32Z [---] followers, [---] engagements


"Results from the [----] SANTORINI study show that currently available combination lipid-lowering therapies led to better LDL-C control after [--] year but only 31% of patients achieved their target levels. These findings highlight the significant unmet need for new lipid-lowering options. https://bit.ly/3U0I4XP https://bit.ly/3U0I4XP"  
[X Link](https://x.com/NewAmsPharma/status/1843273558249619709)  2024-10-07T12:53Z [---] followers, [---] engagements


"In our latest corporate update released this morning we shared our financial results for Q3 and year-to-date and moved the expected release of topline data from our Phase [--] TANDEM study up to Q4. Read more about our strong Q3 and the potential milestones ahead: https://bit.ly/3UGFtCV https://bit.ly/3UGFtCV"  
[X Link](https://x.com/NewAmsPharma/status/1854147861664919895)  2024-11-06T13:04Z [---] followers, [----] engagements


"Out with the old in with the New Were unveiling a fresh new website. Dive into the history of our company our investigational CETP inhibition programs and current research: https://bit.ly/3SLUgLy https://bit.ly/3SLUgLy"  
[X Link](https://x.com/NewAmsPharma/status/1857420218605224210)  2024-11-15T13:47Z [---] followers, [---] engagements


"Familial hypercholesterolemia (FH) is a common genetic disorder that leads to extremely high LDL-C levels. Our Phase [--] BROOKLYN trial focused on patients with this tough-to-treat diagnosis and the results are being shared at #AHA24"  
[X Link](https://x.com/NewAmsPharma/status/1858200931336102393)  2024-11-17T17:30Z [---] followers, [---] engagements


"Guidelines call for patients at very high risk for cardiovascular events to reduce LDL-C below [--] mg/dLa goal only 10% achieve. Professors Kausik Ray and John Kastelein understand that early combination therapy can help more people get to their goals"  
[X Link](https://x.com/NewAmsPharma/status/1920078659089506600)  2025-05-07T11:30Z [---] followers, [----] engagements


"1 in [--] U.S. adultsover [--] million peoplehave high LDL-C a key driver of cardiovascular disease. Managing cholesterol isnt just about numbersits about taking action to reduce your risk of a cardiovascular event"  
[X Link](https://x.com/NewAmsPharma/status/1920078661790925095)  2025-05-07T11:30Z [---] followers, 14.3K engagements


"Late-breaking data from our Phase [--] BROADWAY clinical trial was presented today at #EASCongress2025 and simultaneously published in the New England Journal of Medicine. Read about the results from our largest Phase [--] study to date: https://www.nejm.org/doi/full/10.1056/NEJMoa2415820 https://www.nejm.org/doi/full/10.1056/NEJMoa2415820"  
[X Link](https://x.com/NewAmsPharma/status/1920094044987797628)  2025-05-07T12:31Z [---] followers, [----] engagements


"Maryellen McQuade our Chief People Officer brings deep expertise in organizational development and change management gathered over 25+ years in HR leadership roles across leading pharmaceutical and biotech companies. She has guided HR strategy through significant transformationsfrom product launches and mergers to global expansions and pandemic response. Interested in joining our team Explore our open positions at: https://bit.ly/4lPukec https://bit.ly/4lPukec"  
[X Link](https://x.com/NewAmsPharma/status/1943315461577543702)  2025-07-10T14:24Z [----] followers, [---] engagements


"Annie Neild PhD our Executive Vice President and Head of Global Regulatory Affairs has [--] years of experience in the pharmaceutical industry spanning small molecules peptide therapeutics and biologics. Her deep expertise in guiding investigational therapies from early development through submission helps us navigate complex development pathways effectively. https://bit.ly/3JTylR7 https://bit.ly/3JTylR7"  
[X Link](https://x.com/NewAmsPharma/status/1965808834368397375)  2025-09-10T16:05Z [----] followers, [---] engagements


"Meet Bob Rambo our Head of Pipeline Marketing. With more than [--] years of experience Bob knows what it takes to bring life-changing therapies to market. Hes helped launch blockbuster brands in cardiology and lipid managementand built teams that deliver results. His deep expertise in lipids and passion for innovation positions us for continued success. Learn more about our leadership team: https://www.newamsterdampharma.com/our-leadership/utm_source=x&utm_medium=organic&utm_campaign=leadership&utm_content=rambo"  
[X Link](https://x.com/NewAmsPharma/status/2011096387946233996)  2026-01-13T15:21Z [----] followers, [---] engagements


"New late-breaking data was presented today at #AHA24 from our Phase [--] BROOKLYN clinical trial evaluating the efficacy and safety of obicetrapib our investigational CETP inhibitor in patients with heterozygous familial hypercholesterolemia. https://bit.ly/3YN6mWM https://bit.ly/3YN6mWM"  
[X Link](https://x.com/NewAmsPharma/status/1858616419484922039)  2024-11-18T21:01Z [----] followers, [----] engagements


"Listen in to a fireside chat with three of our senior leaders as part of the @Jefferies London Healthcare Conference on Thursday Nov. [--]. Learn how to join the live webcast or access an archived replay: https://bit.ly/4i9IiXl https://bit.ly/4i9IiXl"  
[X Link](https://x.com/NewAmsPharma/status/1858879144680943941)  2024-11-19T14:24Z [----] followers, [---] engagements


"Were excited to see our Alzheimers disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in @jpreventionalz1. 🔓 Read the open access article: https://bit.ly/49j6Vyq https://bit.ly/49j6Vyq"  
[X Link](https://x.com/NewAmsPharma/status/1980273787640668596)  2025-10-20T14:03Z [----] followers, [----] engagements


"Were looking forward to #AHA25 where our data will be featured in multiple sessions covering: 📊 An analysis of pooled LDL particle data from our Phase [--] programs evaluating our investigational CETP inhibitor 🔬 A preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions Learn more about these upcoming presentations: https://bit.ly/4nyHuwD https://bit.ly/4nyHuwD"  
[X Link](https://x.com/NewAmsPharma/status/1983868449416692185)  2025-10-30T12:07Z [----] followers, [---] engagements


"New this weekend at #AHA25: Dont miss our CSO Dr. @JohnKastelein's oral presentation on an analysis of pooled LDL particle data from our Phase [--] program evaluating our investigational CETP inhibitor. Make sure this session is part of your conference plan: https://eppro02.ativ.me/appinfo.phppage=Session&project=AHA25&id=4368890&server=eppro02.ativ.me https://eppro02.ativ.me/appinfo.phppage=Session&project=AHA25&id=4368890&server=eppro02.ativ.me"  
[X Link](https://x.com/NewAmsPharma/status/1986828300786995489)  2025-11-07T16:09Z [----] followers, [---] engagements


"NEW PHASE [--] DATA: Topline results from our BROADWAY studyour largest Phase [--] clinical trial to dateevaluated obicetrapib our investigational CETP inhibitor in patients with ASCVD and/or HeFH who required additional lowering of their LDL-C levels. https://bit.ly/4gsIDm1 https://bit.ly/4gsIDm1"  
[X Link](https://x.com/NewAmsPharma/status/1866454711030702263)  2024-12-10T12:07Z [----] followers, [----] engagements


"Congratulations to the team on our upsized financing. Together well continue to work to meet the significant unmet need for new safe well-tolerated and convenient LDL-lowering therapies. https://bit.ly/3VEbewZ https://bit.ly/3VEbewZ"  
[X Link](https://x.com/NewAmsPharma/status/1867698922946510928)  2024-12-13T22:31Z [----] followers, [---] engagements


"Our CEO Dr. Michael Davidson and CFO Ian Somaiya will participate in the TD Cowen Healthcare Conference next week in Boston. Join themin person or via live webcastfor a corporate overview on Tuesday March [--] at 1:50 p.m. ET. https://bit.ly/3F7bQWc https://bit.ly/3F7bQWc"  
[X Link](https://x.com/NewAmsPharma/status/1895099234267078870)  2025-02-27T13:10Z [----] followers, [---] engagements


"Today we take a moment to celebrate the outstanding administrative professionals at NewAmsterdam Pharma. Our admin team keeps this organization moving organized and focused on patients. Your hard work and dedication support our efforts to develop innovative therapies for cardiovascular disease and other lipid-related conditions. Thank you for everything you do https://twitter.com/i/web/status/1915132197389979859 https://twitter.com/i/web/status/1915132197389979859"  
[X Link](https://x.com/NewAmsPharma/status/1915132197389979859)  2025-04-23T19:54Z [----] followers, [---] engagements


"Our first quarter was marked by continued clinical execution and investment in our commercial organization to support the potential launch of obicetrapib. Find the details in our latest financial results and corporate update. https://bit.ly/4k9oqDK https://bit.ly/4k9oqDK"  
[X Link](https://x.com/NewAmsPharma/status/1920450486240415755)  2025-05-08T12:07Z [----] followers, [---] engagements


"Hear from our leadership team as part of these upcoming investor conferences in June. Live webcasts and archived replays from each event will be available on our website. https://bit.ly/4mzNMwu https://bit.ly/4mzNMwu"  
[X Link](https://x.com/NewAmsPharma/status/1929666350903185792)  2025-06-02T22:28Z [----] followers, [---] engagements


"We invite you to join our R&D Day webcast on June [--] beginning at 9am ET. Hear from our leadership team as they discuss the latest developments in our clinical program and the future of innovation in cardiovascular care. https://bit.ly/43UH5gb https://bit.ly/43UH5gb"  
[X Link](https://x.com/NewAmsPharma/status/1932422498852757984)  2025-06-10T13:00Z [----] followers, [---] engagements


"Weve had a strong start to [----] sharing compelling new data at multiple conferences and continuing to support our Phase [--] PREVAIL cardiovascular outcomes trial. Review our corporate update and second-quarter financial results: https://bit.ly/3J8iVYF https://bit.ly/3J8iVYF"  
[X Link](https://x.com/NewAmsPharma/status/1953064961665552572)  2025-08-06T12:05Z [----] followers, [---] engagements


"We closed the third quarter with continued momentumadvancing our clinical programs sharing new scientific insights and preparing for whats ahead. Read our latest corporate update and Q3 [----] financial results: https://bit.ly/3LmFtGo https://bit.ly/3LmFtGo"  
[X Link](https://x.com/NewAmsPharma/status/1986115827288969272)  2025-11-05T16:58Z [----] followers, [---] engagements


"Hear exclusive insights from our leadership team at these upcoming November conferences. Live webcasts and archived replays from each event will be available on our website. https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-participate-upcoming-medical-meeting-and-0utm_source=x&utm_medium=organic&utm_campaign=conferences&utm_content=nov https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-participate-upcoming-medical-meeting-and-0utm_source=x&utm_medium=organic&utm_campaign=conferences&utm_content=nov"  
[X Link](https://x.com/NewAmsPharma/status/1988230232789373402)  2025-11-11T13:00Z [----] followers, [---] engagements


"Congratulations to Drs. @AllisonWPeng and @aarti693 on receivingourYoung Researcher Award (YRA)a program supporting early-career investigators advancing innovative research in lipid biology cardiovascular disease and related metabolic conditions. Dr. Peng isa cardiovascular diseasefellow at the Johns Hopkins @CiccaroneCenter whose research focuses on cardiovascular prevention and imaging applying AI and large datasets to improve risk assessment and early detection of ASCVD. She earned her engineering degree from Columbia University and completedherinternal medicine residency at Stanford"  
[X Link](https://x.com/NewAmsPharma/status/2020890817041404191)  2026-02-09T16:01Z [----] followers, [--] engagements


"2024 was a big year NewAmsterdam Pharma. Take a scroll down memory lane to revisit highlights like completing enrollment in our PREVAIL cardiovascular outcomes trial sharing [--] abstracts at the EAS and NLA conferences and presenting data from our BROOKLYN trial at AHA"  
[X Link](https://x.com/NewAmsPharma/status/1869384035748675906)  2024-12-18T14:07Z [----] followers, [---] engagements


"Happy holidays and best wishes for a healthy and happy New Year from all of us at NewAmsterdam Pharma As we look ahead to [----] we are excited to continue to develop potential therapy options to lessen the global impact of cardiovascular disease"  
[X Link](https://x.com/NewAmsPharma/status/1870100761608163473)  2024-12-20T13:35Z [----] followers, [---] engagements


"Join us for a fireside chat with our CFO Ian Somaiya livestreamed from the Guggenheim SMID Cap Biotech Conference on Wed. Feb. [--] at [--] am ET. https://bit.ly/3WJt1TK https://bit.ly/3WJt1TK"  
[X Link](https://x.com/NewAmsPharma/status/1886407020145676747)  2025-02-03T13:30Z [----] followers, [---] engagements


"See our [----] financial performance and plans for the year ahead in our latest corporate update. https://bit.ly/3Xd25Mj https://bit.ly/3Xd25Mj"  
[X Link](https://x.com/NewAmsPharma/status/1894737024877220337)  2025-02-26T13:11Z [----] followers, [---] engagements


"Our CFO Ian Somaiya will participate in the 24th Annual Needham Virtual Healthcare Conference next week. Join him for a virtual fireside chat on Monday April [--] at 12:45 p.m. ET. A live webcast and archived replay will be available. https://bit.ly/4cAfAwp https://bit.ly/4cAfAwp"  
[X Link](https://x.com/NewAmsPharma/status/1907784099193860111)  2025-04-03T13:15Z [----] followers, [---] engagements


"We're less than a week away from #EASCongress2025 where data from our Phase [--] BROADWAY and TANDEM studies will take center stage in late-breaking sessions. Dig into the details as you make your congress plans: https://bit.ly/4jqD6hM https://bit.ly/4jqD6hM"  
[X Link](https://x.com/NewAmsPharma/status/1917551200502964603)  2025-04-30T12:06Z [----] followers, [---] engagements


"Our CFO Ian Somaiya will participate in the [----] RBCCM Global Healthcare Conference next week. Join him for a virtual fireside chat on Tuesday May [--] at 10:00 a.m. ET. A live webcast and archived replay will be available. More info: https://bit.ly/4jVVEH1 https://bit.ly/4jVVEH1"  
[X Link](https://x.com/NewAmsPharma/status/1922985314198380760)  2025-05-15T12:00Z [----] followers, [----] engagements


"Were pleased to share positive topline results from our Alzheimer's Disease biomarker analyses in the Phase [--] BROADWAY trial. Full results will be presented on July 30th at #AAIC2025. Learn more about the study: https://bit.ly/3SIOz0t https://bit.ly/3SIOz0t"  
[X Link](https://x.com/NewAmsPharma/status/1932153612723228845)  2025-06-09T19:11Z [----] followers, [----] engagements


"The curtain is about to rise at #AAIC2025 where full results from the Alzheimers biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: https://bit.ly/4lOSxBO https://bit.ly/4lOSxBO"  
[X Link](https://x.com/NewAmsPharma/status/1947672587175399556)  2025-07-22T14:58Z [----] followers, [----] engagements


"Join our Chief Scientific Officer @JohnKastelein and EVP & Head of Investor Relations Matthew Philippe for a fireside chat during the @Stifel Virtual Cardiometabolic Forum. The livestream starts at [--] a.m. ET tomorrow. https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-present-stifel-2025-virtual-cardiometabolic https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-present-stifel-2025-virtual-cardiometabolic"  
[X Link](https://x.com/NewAmsPharma/status/1972634505635848400)  2025-09-29T12:08Z [----] followers, [---] engagements


"This #ValentinesDay we hope you'll take this to heart: Cardiovascular disease is the leading cause of death among adults worldwide. Learn how our lead investigational candidate obicetrapib could help more people meet their lipid-lowering goals and reduce cardiovascular risk. https://bit.ly/3uEWa7m https://bit.ly/3uEWa7m"  
[X Link](https://x.com/NewAmsPharma/status/1757786265347317997)  2024-02-14T15:17Z [----] followers, [---] engagements


"Taking charge of your heart health is a team effort. Clinical recommendations help guide prevention screening and treatmentwhile your actions like tracking risk factors and adopting healthy habits make the difference. Learn more about preventing heart disease from https://www.heart.org/en/healthy-living/healthy-lifestyle/how-to-help-prevent-heart-disease-at-any-age https://www.heart.org/en/healthy-living/healthy-lifestyle/how-to-help-prevent-heart-disease-at-any-age"  
[X Link](https://x.com/NewAmsPharma/status/1995879207508103368)  2025-12-02T15:34Z [----] followers, [---] engagements


"Matthew Philippe our Executive Vice President and Head of Investor Relations is a driving force behind our strategic growth. With over two decades of experience in healthcare investing and corporate finance Matt contributes deep industry insight and a global perspective to our investor engagement efforts. https://www.newamsterdampharma.com/our-leadership/utm_source=x&utm_medium=organic&utm_campaign=leadership&utm_content=philippe https://www.newamsterdampharma.com/our-leadership/utm_source=x&utm_medium=organic&utm_campaign=leadership&utm_content=philippe"  
[X Link](https://x.com/NewAmsPharma/status/1998054987335979359)  2025-12-08T15:40Z [----] followers, [---] engagements


"Low rates of Lp(a) testing mean many patients may miss a critical opportunity to address residual cardiovascular risk. A study in @JAHA_AHA found that testing for Lp(a) regardless of the result is associated with greater initiation of lipid-lowering therapy including non-statin options when results show elevated Lp(a) levels. This highlights the urgent need to increase awareness of Lp(a) testingnot only for identifying risk but for its role in driving treatment decisions and improving long-term management. Learn more about residual cardiovascular risk:"  
[X Link](https://x.com/NewAmsPharma/status/2008559844815786129)  2026-01-06T15:22Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing